KRTX - Karuna Therapeutics GAAP EPS of -$2.17 misses by $0.10 revenue of $5.28M
- Karuna Therapeutics press release ( NASDAQ: KRTX ): Q2 GAAP EPS of -$2.17 misses by $0.10 .
- Revenue of $5.28M.
-
The Company ended the quarter with $407.4 million in cash, cash equivalents and available-for-sale investment securities compared to $494.0 million as of December 31, 2021. The Company expects that current cash, cash equivalents and available-for-sale investment securities as of June 30, 2022 will enable the Company to fund its operating expenses and capital expenditure requirements for at least 12 months following the potential NDA submission of KarXT for the treatment of psychosis in adults with schizophrenia.
- Shares +8.29% PM.
For further details see:
Karuna Therapeutics GAAP EPS of -$2.17 misses by $0.10, revenue of $5.28M